[Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder]

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023 Jun;45(3):429-435. doi: 10.3881/j.issn.1000-503X.15514.
[Article in Chinese]

Abstract

Objective To investigate the clinicopathological features,immunohistochemical features,diagnosis,and relationship with sporadic prostate cancer in primary small cell neuroendocrine carcinoma of the bladder. Methods We retrospectively analyzed the clinical characteristics of 12 patients with primary small cell neuroendocrine carcinoma of the bladder diagnosed at Beijing Chao-Yang Hospital affiliated to Capital Medical University from January 2013 to September 2022.The histological features of primary small cell neuroendocrine carcinoma of the bladder were re-evaluated by two pathologists according to the 2022 revision of the World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs.Electronic medical records were retrieved,and telephone follow-up was conducted from the time of histopathological diagnosis to the death or the end of the last follow-up until January 31,2023. Results The 12 patients include 7 patients in pT3 stage and 1 patient in pT4 stage.Eight patients were complicated with other types of tumors,such as high-grade urothelial carcinoma of the bladder and squamous cell carcinoma.Five patients had sporadic prostate cancer.Immunohistochemical staining showed that 12 (100.0%),10 (83.3%),and 8 (66.7%) patients were tested positive for CD56,Syn,and CgA,respectively.The Ki67 proliferation index ranged from 80% to 90%.Five patients with urothelial carcinoma were tested positive for CK20,GATA3,and CK7.P504S was positive in all the 5 patients with prostate cancer,while P63 and 34βE12 were negative.The follow-up of the 12 patients lasted for 3-60 months.Eight of these patients died during follow-up,with the median survival of 15.5 months.Four patients survived. Conclusions Primary small cell neuroendocrine carcinoma of the bladder is a rare urological tumor with high aggressiveness and poor prognosis.In male patients with bladder prostatectomy,all prostate tissue should be sampled.If prostate cancer is detected,the prostate-specific antigen level should be monitored.

目的 探讨原发性膀胱小细胞神经内分泌癌临床病理特征、免疫组织化学特点、诊断及与偶发前列腺癌的关系。方法 回顾性分析2013年1月至2022年9月在首都医科大学附属北京朝阳医院就诊的12例原发性膀胱小细胞神经内分泌癌患者的临床资料,经病理科2位副主任医师重新阅片后,按照2022版泌尿系统及男性生殖器官肿瘤世界卫生组织分类进行复核。通过检索电子病历及电话进行随访,随访自病理确诊开始至患者死亡或最后一次随访结束,截止日期2023年1月31日。结果 12例患者中,7例为pT3期,1例为pT4期;8例合并膀胱高级别尿路上皮癌、鳞状细胞癌等其他类型肿瘤,5例合并偶发前列腺癌。免疫组织化学染色结果显示,12例患者中,12例(100.0%)CD56阳性,10例(83.3%)Syn阳性,8例(66.7%)CgA阳性,Ki67增殖指数介于80%~90%;5例尿路上皮癌CK20、GATA3和CK7均为阳性;5例前列腺癌P504S 均为阳性,P63和34βE12均为阴性。随访时间3~60个月,8例患者在随访期间死亡,中位生存时间15.5个月;4例患者生存。结论 原发性膀胱小细胞神经内分泌癌是罕见的泌尿系统肿瘤,侵袭性强,预后差。男性膀胱前列腺切除患者,前列腺组织应全部取材。如发现具有临床意义的前列腺癌,术后应监测前列腺特异性抗原水平。.

Keywords: clinicopathological features; immunophenotyping; prostate cancer; small cell neuroendocrine carcinoma of the bladder.

Publication types

  • English Abstract

MeSH terms

  • Biomarkers, Tumor
  • Carcinoma, Neuroendocrine* / diagnosis
  • Carcinoma, Neuroendocrine* / metabolism
  • Carcinoma, Neuroendocrine* / pathology
  • Carcinoma, Transitional Cell* / pathology
  • Humans
  • Male
  • Prostatic Neoplasms*
  • Retrospective Studies
  • Urinary Bladder / metabolism
  • Urinary Bladder / pathology
  • Urinary Bladder Neoplasms* / pathology

Substances

  • Biomarkers, Tumor